A polyp is a growth in the intestinal lining of the digestive system, specifically in the colon and/or rectum. 85% of colorectal cancers develop from adenomatous polyps which is why they are referred to as pre-cancerous.
PolypDx™ is a urine test to detect adenomatous polyps, the precursor to colorectal cancer.
PolypDx™ is designed for both men and women who are at average risk for colorectal cancer: 50-74 years of age.
PolypDx™ is not intended for use in high risk individuals and is not a replacement for colonoscopy. You may be a high risk individual if you have a personal history of colorectal cancer or polyps.
PolypDx™ measures small molecules (metabolites) in urine samples to detect the presence of polyps in the colon and rectum. These metabolites are the by-products of cellular metabolism and discarded in urine.
By indicating the likely presence or absence of an adenomatous polyp, PolypDx™ may help to provide more information about whether additional follow-up, such as a colonoscopy, should be considered.
Urine collection is more convenient compared to any other specimen collection.
PolypDx™ predicts the likelihood of polyps presence by analyzing the level of metabolomics markers in urine.
Researchers at the University of Alberta, in Edmonton, Canada, wanted to find a better way to screen for colorectal cancer. A clinical trial of 1,000 participants was conducted for the research and development of a biomarker panel. The test was further validated in subsequent clinical trials.
PolypDx™ detects 78% of polyps in average risk patients.
PolypDx™ is a screening test. Any positive result should be discussed with your doctor to determine the next steps, such as a colonoscopy.
There are no special dietary restrictions and you do not need to stop taking any of your current medications prior to collecting a sample for PolypDx™.
For further information, speak to your doctor about PolypDx™.